title: Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
abstract: Mood stabilizers form a cornerstone in the long-term treatment of bipolar disorder. The first representative of their family was lithium, still considered a prototype drug for the prevention of manic and depressive recurrences in bipolar disorder. Along with carbamazepine and valproates, lithium belongs to the first generation of mood stabilizers, which appeared in psychiatric treatment in the 1960s. Atypical antipsychotics with mood-stabilizing properties and lamotrigine, which were introduced in the mid-1990 s, form the second generation of such drugs. The response of patients with bipolar disorder to mood stabilizers has different levels of magnitude. About one-third of lithium-treated patients are excellent responders, showing total prevention of the episodes, and these patients are clinically characterized by an episodic clinical course, complete remission, a bipolar family history, low psychiatric co-morbidity and a hyperthymic temperament. It has been suggested that responders to carbamazepine or lamotrigine may differ clinically from responders to lithium. The main phenotype of the response to mood stabilizers is a degree of prevention against recurrences of manic and depressive episodes during long-term treatment. The most specific scale in this respect is the so-called Alda scale, where retrospective assessment of lithium response is scored on a 0-10 scale. The vast majority of data on genetic influences on the response to mood stabilizers has been gathered in relation to lithium. The studies on the mechanisms of action of lithium and on the neurobiology of bipolar disorder have led to the identification of a number of candidate genes. The genes studied for their association with lithium response have been those connected with neurotransmitters (serotonin, dopamine and glutamate), second messengers (phosphatidyl inositol [PI], cyclic adenosine-monophosphate [cAMP] and protein kinase C [PKC] pathways), substances involved in neuroprotection (brain-derived neurotrophic factor [BDNF] and glycogen synthase kinase 3-β [GSK-3β]) and a number of other miscellaneous genes. There are no published pharmacogenomic studies of mood stabilizers other than lithium, except for one study of the X-box binding protein 1 (XBP1) gene in relation to the efficacy of valproate. In recent years, a number of genome-wide association studies (GWAS) in bipolar disorders have been performed and some of those have also focused on lithium response. They suggest roles for the glutamatergic receptor AMPA (GRIA2) gene and the amiloride-sensitive cation channel 1 neuronal (ACCN1) gene in long-term lithium response. A promise for better elucidating the genetics of lithium response has been created by the formation of the Consortium on Lithium Genetics (ConLiGen) to establish the largest sample, to date, for the GWAS of lithium response in bipolar disorder. The sample currently comprises more than 1,200 patients, characterized by their response to lithium treatment according to the Alda scale. Preliminary results from this international study suggest a possible involvement of the sodium bicarbonate transporter (SLC4A10) gene in lithium response. It is concluded that the pharmacogenetics of response to mood stabilizers has recently become a growing field of research, especially so far as the pharmacogenetics of the response to lithium is concerned. Clearly, the ConLiGen project is a highly significant step in this research. Although the results of pharmacogenetic studies are of significant scientific value, their possible practical implications are yet to be seen.
authors: Department of Adult Psychiatry, Poznan University of Medical Sciences, ul.Szpitalna 27/33, 60-572, Poznan, Poland. janusz.rybakowski@gmail.com
authors: Janusz K
authors: JK
authors: Rybakowski
mesh_terms: D018692:Antimanic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D018020:Lithium Compounds / Q000494:pharmacology / Q000627:therapeutic use; D010597:Pharmacogenetics; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D018692:Antimanic Agents; D014150:Antipsychotic Agents; D018020:Lithium Compounds
references: Arch Neurol. 2008 Apr;65(4):550-3
references: 18413482
references: Bipolar Disord. 2001 Apr;3(2):63-7
references: 11333064
references: Am J Med Genet. 2002 May 8;114(4):370-9
references: 11992559
references: J Affect Disord. 2013 Feb 20;145(2):187-9
references: 22939170
references: Neuromolecular Med. 2009;11(2):128-32
references: 19536654
references: Pharmacogenet Genomics. 2008 May;18(5):403-12
references: 18408563
references: J Psychiatr Res. 2000 Mar-Apr;34(2):89-98
references: 10758249
references: Am J Med Genet B Neuropsychiatr Genet. 2008 Jun 5;147B(4):500-4
references: 18189280
references: Arch Gen Psychiatry. 2003 May;60(5):497-502
references: 12742871
references: J Clin Psychiatry. 1995 Mar;56(3):108-12
references: 7883728
references: Pharmacol Rep. 2005 Nov-Dec;57(6):761-5
references: 16382194
references: Am J Psychiatry. 1989 Jan;146(1):81-3
references: 2492164
references: Bipolar Disord. 2003 Apr;5(2):110-4
references: 12680900
references: Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):37-8
references: 15704231
references: Am J Physiol. 1979 Jul;237(1):C102-10
references: 464037
references: Psychiatry Res. 1999 Jul 30;87(1):7-19
references: 10512150
references: Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58
references: 22137564
references: World J Biol Psychiatry. 2006;7(3):158-61
references: 16861141
references: Psychiatry Res. 2009 Aug 15;168(3):209-12
references: 19564049
references: Pharmacogenomics J. 2001;1(1):71-7
references: 11913731
references: Med J Aust. 1949 Sep 3;2(10):349-52
references: 18142718
references: Biol Psychiatry. 2010 Jul 15;68(2):156-62
references: 20227682
references: Int J Neuropsychopharmacol. 2003 Dec;6(4):421-4
references: 14604458
references: J Affect Disord. 2006 Jul;93(1-3):13-7
references: 16650901
references: Neuropsychobiology. 2000;42 Suppl 1:2-10
references: 11093063
references: Neuropsychobiology. 2010;62(1):72-8
references: 20453537
references: Neurosci Lett. 2005 Mar 7;376(1):51-5
references: 15694273
references: Folia Psychiatr Neurol Jpn. 1973;27(4):283-97
references: 4801623
references: Mol Psychiatry. 2008 Feb;13(2):197-207
references: 17486107
references: Arch Gen Psychiatry. 2008 Jan;65(1):53-61
references: 18180429
references: Pharmacol Res. 2008 May;57(5):369-73
references: 18456508
references: J Ment Health. 2010 Apr;19(2):142-56
references: 20433322
references: PLoS One. 2012;7(2):e32091
references: 22384149
references: Pharmacopsychiatry. 1985 Mar;18(2):214-7
references: 3927331
references: Pharmacogenomics. 2010 Oct;11(10):1439-65
references: 21047205
references: J Clin Psychiatry. 1995 Sep;56(9):411-7
references: 7665540
references: Int J Neuropsychopharmacol. 2006 Feb;9(1):83-8
references: 15927087
references: Hum Psychopharmacol. 2009 Jun;24(4):287-91
references: 19330793
references: Neurosci Lett. 2009 Dec 25;467(2):67-71
references: 19818381
references: Mol Diagn Ther. 2007;11(3):161-70
references: 17570738
references: Int J Neuropsychopharmacol. 1998 Dec;1(2):125-129
references: 11281956
references: Genome Med. 2009 Aug 19;1(8):79
references: 19691823
references: CNS Neurosci Ther. 2012 Mar;18(3):214-8
references: 22070572
references: Genes Brain Behav. 2011 Nov;10(8):852-61
references: 21781277
references: J Psychopharmacol. 2012 Mar;26(3):368-73
references: 21890592
references: Eur Neuropsychopharmacol. 2012 May;22(5):339-46
references: 22000157
references: Ann Med Psychol (Paris). 1971 Oct;2(3):442-8
references: 5128637
references: Neuro Endocrinol Lett. 2011;32(4):545-51
references: 21876507
references: Neurosci Lett. 2006 Aug 7;403(3):288-93
references: 16787706
references: J Clin Psychiatry. 2002 Oct;63(10):942-7
references: 12416605
references: Pharmacogenomics. 2011 Nov;12(11):1559-69
references: 21961650
references: Eur Psychiatry. 2003 May;18(3):129-32
references: 12763299
references: Pharmacogenetics. 1998 Jun;8(3):259-68
references: 9682271
references: Psychiatry Res. 2009 Sep 30;169(2):164-6
references: 19647327
references: Pharmacogenomics J. 2005;5(1):35-41
references: 15505643
references: Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):640-50
references: 21630437
references: Psychiatr Genet. 1999 Mar;9(1):13-6
references: 10335547
references: Mol Psychiatry. 2001 Sep;6(5):570-8
references: 11526471
references: Bipolar Disord. 2002;4 Suppl 1:21-5
references: 12479671
references: Psychiatr Genet. 1999 Mar;9(1):23-34
references: 10335549
references: Neuropsychobiology. 2010;62(1):61-71
references: 20453536
references: Neuropsychobiology. 2009;59(3):178-83
references: 19468241
references: J Clin Psychiatry. 2002 Feb;63(2):146-51
references: 11874216
references: Pharmacopsychiatry. 2009 Jan;42(1):20-2
references: 19153942
references: Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):820-3
references: 17373693
references: Biol Psychiatry. 2005 May 15;57(10):1097-102
references: 15866548
references: Hum Psychopharmacol. 2011 Mar;26(2):168-71
references: 21437990
references: J Clin Psychiatry. 2008 May;69(5):862-3
references: 18681763
references: Am J Psychiatry. 2009 Jun;166(6):718-25
references: 19448189
references: J Psychiatr Res. 1999 Sep-Oct;33(5):371-7
references: 10504005
references: Pharmacogenomics J. 2004;4(4):267-73
references: 15111989
references: Pharmacol Rep. 2009 May-Jun;61(3):448-52
references: 19605943
references: Int J Neuropsychopharmacol. 2007 Oct;10(5):709-11
references: 17982754
references: BMC Psychiatry. 2007 Feb 26;7:9
references: 17324276
references: J Affect Disord. 2001 Feb;62(3):151-64
references: 11223103
references: Nat Genet. 2003 Oct;35(2):171-5
references: 12949534
references: Bipolar Disord. 2011 Nov-Dec;13(7-8):630-7
references: 22085476
references: J Biol Rhythms. 2010 Apr;25(2):132-7
references: 20348464
references: Neuropsychobiology. 2010;62(1):8-16
references: 20453530
references: Pharmacogenomics. 2008 Nov;9(11):1595-603
references: 19018715
references: Br J Psychiatry. 1963 Nov;109:810-4
references: 14080575
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):204-8
references: 17822820
references: Pharmacol Rep. 2005 Jan-Feb;57(1):124-7
references: 15849387
references: Psychiatr Genet. 2006 Apr;16(2):49-50
references: 16538178
references: Pharmacopsychiatry. 2005 Jul;38(4):166-70
references: 16025419